Traverse Biotech has been awarded a Phase I SBIR grant from the National Cancer Institute to develop targeted immunotherapy for selected solid tumors - BioSpace

Traverse Biotech, Inc. received a Phase 1 SBIR Grant from the NCI to develop a bispecific antibody for treating Non-small Cell Lung Cancer. The grant supports validating a novel tumor antigen and advancing cancer immunotherapy. Traverse Biotech focuses on accelerating therapeutic development through partnerships and a lean operating structure.